| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumococcal Vaccines | 100 | 2025 | 278 | 21.310 |
Why?
|
| Pneumococcal Infections | 88 | 2025 | 299 | 18.350 |
Why?
|
| Infant | 377 | 2025 | 2244 | 18.310 |
Why?
|
| Streptococcal Infections | 63 | 2024 | 184 | 16.280 |
Why?
|
| Streptococcus pneumoniae | 93 | 2025 | 336 | 15.180 |
Why?
|
| Humans | 633 | 2025 | 14537 | 14.630 |
Why?
|
| Streptococcus agalactiae | 69 | 2024 | 202 | 14.000 |
Why?
|
| HIV Infections | 189 | 2024 | 5097 | 13.730 |
Why?
|
| Respiratory Tract Infections | 70 | 2024 | 266 | 13.530 |
Why?
|
| Pregnancy Complications, Infectious | 68 | 2025 | 529 | 13.170 |
Why?
|
| Respiratory Syncytial Virus Infections | 57 | 2025 | 200 | 12.240 |
Why?
|
| Vaccination | 89 | 2024 | 365 | 11.560 |
Why?
|
| Influenza, Human | 67 | 2023 | 374 | 11.350 |
Why?
|
| Female | 383 | 2025 | 9103 | 11.100 |
Why?
|
| Antibodies, Bacterial | 45 | 2025 | 153 | 11.080 |
Why?
|
| Antibodies, Viral | 58 | 2025 | 284 | 10.650 |
Why?
|
| Child, Preschool | 234 | 2024 | 1748 | 10.530 |
Why?
|
| Infant, Newborn | 199 | 2025 | 1479 | 9.960 |
Why?
|
| Nasopharynx | 55 | 2024 | 151 | 9.710 |
Why?
|
| South Africa | 302 | 2025 | 7596 | 9.630 |
Why?
|
| Pneumonia | 53 | 2024 | 131 | 9.520 |
Why?
|
| Vaccines, Conjugate | 71 | 2025 | 171 | 9.290 |
Why?
|
| Hospitalization | 72 | 2024 | 418 | 8.570 |
Why?
|
| Male | 271 | 2025 | 6754 | 8.540 |
Why?
|
| Influenza Vaccines | 38 | 2022 | 144 | 8.370 |
Why?
|
| Respiratory Syncytial Virus, Human | 37 | 2025 | 155 | 8.280 |
Why?
|
| Child | 171 | 2024 | 2242 | 7.700 |
Why?
|
| Pregnancy | 123 | 2025 | 1862 | 7.550 |
Why?
|
| Immunoglobulin G | 39 | 2025 | 231 | 7.530 |
Why?
|
| Carrier State | 30 | 2024 | 92 | 7.450 |
Why?
|
| Immunization Schedule | 30 | 2025 | 81 | 6.460 |
Why?
|
| Pneumonia, Viral | 26 | 2024 | 104 | 6.250 |
Why?
|
| Vaccines | 21 | 2024 | 86 | 6.250 |
Why?
|
| Immunization Programs | 27 | 2024 | 81 | 5.090 |
Why?
|
| Serogroup | 38 | 2025 | 150 | 5.060 |
Why?
|
| Rotavirus Infections | 17 | 2020 | 46 | 4.880 |
Why?
|
| Adult | 142 | 2025 | 5913 | 4.830 |
Why?
|
| Streptococcal Vaccines | 21 | 2024 | 47 | 4.810 |
Why?
|
| Haemophilus Vaccines | 21 | 2021 | 41 | 4.760 |
Why?
|
| Rotavirus Vaccines | 18 | 2021 | 53 | 4.740 |
Why?
|
| Pneumonia, Pneumococcal | 30 | 2023 | 100 | 4.500 |
Why?
|
| Immunization, Secondary | 21 | 2025 | 72 | 4.470 |
Why?
|
| AIDS-Related Opportunistic Infections | 19 | 2021 | 195 | 4.390 |
Why?
|
| Immunogenicity, Vaccine | 27 | 2025 | 103 | 4.330 |
Why?
|
| Coinfection | 32 | 2024 | 276 | 4.290 |
Why?
|
| Whooping Cough | 11 | 2024 | 36 | 4.230 |
Why?
|
| Infant, Newborn, Diseases | 18 | 2023 | 73 | 4.130 |
Why?
|
| Incidence | 65 | 2024 | 685 | 4.050 |
Why?
|
| Antibodies, Neutralizing | 26 | 2025 | 303 | 4.040 |
Why?
|
| Prevalence | 63 | 2024 | 1192 | 4.020 |
Why?
|
| Prospective Studies | 64 | 2024 | 1160 | 3.870 |
Why?
|
| Premature Birth | 10 | 2025 | 80 | 3.870 |
Why?
|
| Pandemics | 18 | 2024 | 296 | 3.790 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 18 | 2024 | 42 | 3.780 |
Why?
|
| HIV-1 | 31 | 2024 | 1260 | 3.750 |
Why?
|
| Immunity, Maternally-Acquired | 11 | 2023 | 40 | 3.640 |
Why?
|
| Coronavirus Infections | 8 | 2021 | 71 | 3.560 |
Why?
|
| Pneumonia, Bacterial | 23 | 2018 | 54 | 3.500 |
Why?
|
| Anti-Bacterial Agents | 28 | 2024 | 293 | 3.470 |
Why?
|
| Case-Control Studies | 44 | 2024 | 480 | 3.420 |
Why?
|
| Paramyxoviridae Infections | 13 | 2024 | 27 | 3.410 |
Why?
|
| Adolescent | 89 | 2024 | 2985 | 3.390 |
Why?
|
| Young Adult | 79 | 2025 | 2498 | 3.360 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 10 | 2021 | 28 | 3.170 |
Why?
|
| Hepatitis B Vaccines | 11 | 2024 | 40 | 3.080 |
Why?
|
| Tuberculosis | 20 | 2023 | 543 | 2.940 |
Why?
|
| Metapneumovirus | 12 | 2024 | 30 | 2.900 |
Why?
|
| Infectious Disease Transmission, Vertical | 18 | 2022 | 472 | 2.890 |
Why?
|
| Anti-Retroviral Agents | 13 | 2021 | 551 | 2.850 |
Why?
|
| Tuberculosis, Pulmonary | 15 | 2017 | 324 | 2.830 |
Why?
|
| Haemophilus influenzae | 14 | 2023 | 42 | 2.790 |
Why?
|
| Risk Factors | 66 | 2024 | 1475 | 2.780 |
Why?
|
| Specimen Handling | 8 | 2019 | 105 | 2.700 |
Why?
|
| Population Surveillance | 27 | 2021 | 325 | 2.700 |
Why?
|
| Developing Countries | 27 | 2024 | 400 | 2.690 |
Why?
|
| Stillbirth | 22 | 2024 | 83 | 2.680 |
Why?
|
| Double-Blind Method | 39 | 2025 | 272 | 2.670 |
Why?
|
| Cause of Death | 23 | 2024 | 221 | 2.660 |
Why?
|
| Picornaviridae Infections | 5 | 2021 | 18 | 2.650 |
Why?
|
| Child Mortality | 22 | 2024 | 96 | 2.580 |
Why?
|
| Virus Diseases | 10 | 2023 | 55 | 2.530 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 8 | 2025 | 14 | 2.490 |
Why?
|
| Staphylococcus aureus | 12 | 2023 | 43 | 2.480 |
Why?
|
| Poliovirus Vaccine, Inactivated | 7 | 2021 | 17 | 2.310 |
Why?
|
| Rhinovirus | 6 | 2021 | 23 | 2.280 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 13 | 2020 | 54 | 2.240 |
Why?
|
| Measles Vaccine | 8 | 2024 | 34 | 2.240 |
Why?
|
| Cytomegalovirus Infections | 5 | 2021 | 23 | 2.230 |
Why?
|
| Global Health | 35 | 2024 | 193 | 2.220 |
Why?
|
| Polysaccharides, Bacterial | 10 | 2020 | 35 | 2.150 |
Why?
|
| Child Health | 23 | 2024 | 77 | 2.120 |
Why?
|
| Gastroenteritis | 9 | 2021 | 22 | 2.110 |
Why?
|
| Spike Glycoprotein, Coronavirus | 12 | 2024 | 101 | 2.100 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 5 | 2023 | 11 | 2.070 |
Why?
|
| Bacterial Infections | 9 | 2020 | 54 | 2.060 |
Why?
|
| HIV Seropositivity | 9 | 2023 | 265 | 2.060 |
Why?
|
| Community-Acquired Infections | 17 | 2023 | 102 | 2.030 |
Why?
|
| Mycobacterium tuberculosis | 14 | 2018 | 329 | 2.030 |
Why?
|
| Vaccines, Combined | 14 | 2024 | 34 | 2.020 |
Why?
|
| Middle Aged | 61 | 2025 | 3601 | 1.990 |
Why?
|
| Bacterial Vaccines | 6 | 2024 | 13 | 1.990 |
Why?
|
| Bordetella pertussis | 6 | 2023 | 29 | 1.960 |
Why?
|
| Diarrhea | 11 | 2021 | 76 | 1.940 |
Why?
|
| Tetanus | 3 | 2023 | 10 | 1.890 |
Why?
|
| Diphtheria | 3 | 2023 | 16 | 1.880 |
Why?
|
| Antitubercular Agents | 13 | 2021 | 322 | 1.860 |
Why?
|
| Rotavirus | 10 | 2021 | 29 | 1.840 |
Why?
|
| Randomized Controlled Trials as Topic | 23 | 2024 | 244 | 1.830 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2025 | 77 | 1.820 |
Why?
|
| Radiography, Thoracic | 11 | 2020 | 19 | 1.810 |
Why?
|
| Cost of Illness | 18 | 2023 | 167 | 1.790 |
Why?
|
| HIV | 11 | 2023 | 380 | 1.780 |
Why?
|
| Time Factors | 19 | 2024 | 507 | 1.700 |
Why?
|
| World Health Organization | 17 | 2023 | 137 | 1.700 |
Why?
|
| Immunization | 13 | 2022 | 63 | 1.680 |
Why?
|
| Vaccination Coverage | 6 | 2024 | 13 | 1.680 |
Why?
|
| Africa | 26 | 2024 | 376 | 1.660 |
Why?
|
| Viral Vaccines | 6 | 2022 | 24 | 1.640 |
Why?
|
| Sputum | 10 | 2017 | 135 | 1.620 |
Why?
|
| Real-Time Polymerase Chain Reaction | 16 | 2023 | 90 | 1.600 |
Why?
|
| Antiviral Agents | 13 | 2025 | 111 | 1.570 |
Why?
|
| Vagina | 10 | 2022 | 91 | 1.570 |
Why?
|
| Aged | 44 | 2024 | 1740 | 1.540 |
Why?
|
| Haemophilus influenzae type b | 10 | 2020 | 17 | 1.510 |
Why?
|
| Klebsiella pneumoniae | 5 | 2024 | 39 | 1.480 |
Why?
|
| Tuberculosis, Ocular | 2 | 2022 | 2 | 1.470 |
Why?
|
| Uveitis | 2 | 2022 | 5 | 1.470 |
Why?
|
| Haemophilus Infections | 13 | 2017 | 23 | 1.470 |
Why?
|
| Neonatal Sepsis | 4 | 2022 | 29 | 1.470 |
Why?
|
| Cross-Sectional Studies | 24 | 2024 | 1422 | 1.460 |
Why?
|
| Poliomyelitis | 3 | 2024 | 5 | 1.460 |
Why?
|
| Bacterial Capsules | 10 | 2022 | 33 | 1.450 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 5 | 2018 | 226 | 1.420 |
Why?
|
| Retrospective Studies | 23 | 2024 | 799 | 1.420 |
Why?
|
| Sepsis | 9 | 2024 | 102 | 1.410 |
Why?
|
| Viruses | 9 | 2024 | 47 | 1.400 |
Why?
|
| Genotype | 14 | 2020 | 442 | 1.390 |
Why?
|
| Bacterial Proteins | 8 | 2024 | 119 | 1.380 |
Why?
|
| Rectum | 6 | 2020 | 22 | 1.370 |
Why?
|
| Cohort Studies | 23 | 2024 | 967 | 1.370 |
Why?
|
| Respiratory Syncytial Viruses | 12 | 2023 | 28 | 1.370 |
Why?
|
| Treatment Outcome | 26 | 2023 | 889 | 1.360 |
Why?
|
| Seasons | 23 | 2024 | 154 | 1.340 |
Why?
|
| Politics | 2 | 2021 | 24 | 1.320 |
Why?
|
| Serotyping | 21 | 2023 | 66 | 1.300 |
Why?
|
| Staphylococcal Infections | 5 | 2015 | 31 | 1.300 |
Why?
|
| Bayes Theorem | 10 | 2024 | 81 | 1.290 |
Why?
|
| Milk, Human | 5 | 2022 | 23 | 1.280 |
Why?
|
| Infant, Premature | 12 | 2025 | 56 | 1.280 |
Why?
|
| Measles | 6 | 2020 | 36 | 1.260 |
Why?
|
| Severity of Illness Index | 17 | 2024 | 253 | 1.220 |
Why?
|
| Bacteria | 11 | 2024 | 47 | 1.210 |
Why?
|
| Autopsy | 15 | 2024 | 140 | 1.200 |
Why?
|
| Multiplex Polymerase Chain Reaction | 3 | 2018 | 23 | 1.200 |
Why?
|
| Nervous System Diseases | 3 | 2024 | 14 | 1.190 |
Why?
|
| Neoplasms | 2 | 2020 | 147 | 1.190 |
Why?
|
| Measles virus | 2 | 2019 | 6 | 1.170 |
Why?
|
| Cross Infection | 3 | 2023 | 52 | 1.110 |
Why?
|
| DNA, Bacterial | 9 | 2021 | 53 | 1.110 |
Why?
|
| Phylogeny | 18 | 2020 | 231 | 1.110 |
Why?
|
| Prenatal Care | 4 | 2024 | 147 | 1.100 |
Why?
|
| Chickenpox Vaccine | 2 | 2020 | 6 | 1.070 |
Why?
|
| Communicable Disease Control | 6 | 2020 | 101 | 1.070 |
Why?
|
| Age Factors | 21 | 2021 | 370 | 1.060 |
Why?
|
| Mothers | 9 | 2023 | 195 | 1.050 |
Why?
|
| Health Priorities | 5 | 2021 | 62 | 1.040 |
Why?
|
| Clinical Laboratory Techniques | 4 | 2020 | 56 | 1.040 |
Why?
|
| Meningitis, Bacterial | 9 | 2024 | 38 | 1.030 |
Why?
|
| Bacteremia | 12 | 2019 | 79 | 1.030 |
Why?
|
| Coronavirus | 4 | 2021 | 14 | 1.030 |
Why?
|
| Antibody Formation | 10 | 2024 | 61 | 1.030 |
Why?
|
| Mortality | 7 | 2021 | 104 | 1.020 |
Why?
|
| Poliovirus Vaccines | 3 | 2019 | 11 | 1.010 |
Why?
|
| Influenza B virus | 9 | 2017 | 42 | 1.010 |
Why?
|
| Child Health Services | 5 | 2020 | 35 | 1.010 |
Why?
|
| Clinical Trials as Topic | 12 | 2020 | 112 | 1.000 |
Why?
|
| Pneumonia, Pneumocystis | 6 | 2017 | 16 | 0.990 |
Why?
|
| Health Policy | 7 | 2024 | 140 | 0.990 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 256 | 0.980 |
Why?
|
| C-Reactive Protein | 7 | 2021 | 96 | 0.980 |
Why?
|
| Seroepidemiologic Studies | 7 | 2023 | 109 | 0.970 |
Why?
|
| Cytomegalovirus | 4 | 2021 | 24 | 0.970 |
Why?
|
| Asthma | 3 | 2023 | 33 | 0.970 |
Why?
|
| Immunity, Herd | 4 | 2021 | 4 | 0.960 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 13 | 2020 | 150 | 0.950 |
Why?
|
| Membrane Proteins | 5 | 2024 | 36 | 0.930 |
Why?
|
| Health Facilities | 3 | 2024 | 40 | 0.910 |
Why?
|
| Immunity, Humoral | 5 | 2023 | 42 | 0.910 |
Why?
|
| HIV Seronegativity | 5 | 2021 | 52 | 0.910 |
Why?
|
| Pregnancy Outcome | 10 | 2022 | 117 | 0.910 |
Why?
|
| Perinatal Death | 5 | 2023 | 33 | 0.900 |
Why?
|
| Islam | 2 | 2021 | 5 | 0.890 |
Why?
|
| Vaccines, Attenuated | 12 | 2020 | 28 | 0.890 |
Why?
|
| Bacteriological Techniques | 9 | 2017 | 54 | 0.880 |
Why?
|
| Sensitivity and Specificity | 18 | 2021 | 385 | 0.880 |
Why?
|
| Infant, Low Birth Weight | 6 | 2025 | 35 | 0.870 |
Why?
|
| Poverty | 7 | 2020 | 152 | 0.870 |
Why?
|
| Nanoparticles | 2 | 2022 | 104 | 0.860 |
Why?
|
| Longitudinal Studies | 8 | 2022 | 435 | 0.860 |
Why?
|
| Klebsiella Infections | 1 | 2024 | 13 | 0.860 |
Why?
|
| Hemagglutination Inhibition Tests | 7 | 2020 | 23 | 0.860 |
Why?
|
| Viral Fusion Proteins | 7 | 2025 | 13 | 0.840 |
Why?
|
| Pertussis Vaccine | 4 | 2024 | 16 | 0.840 |
Why?
|
| Hospitals | 9 | 2023 | 103 | 0.830 |
Why?
|
| Antibodies, Monoclonal | 6 | 2025 | 142 | 0.830 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 370 | 0.820 |
Why?
|
| Viral Load | 7 | 2020 | 819 | 0.820 |
Why?
|
| Polysaccharides | 3 | 2024 | 45 | 0.820 |
Why?
|
| Health Services Accessibility | 4 | 2024 | 280 | 0.820 |
Why?
|
| Candida | 1 | 2023 | 24 | 0.820 |
Why?
|
| Patient Acuity | 6 | 2022 | 18 | 0.820 |
Why?
|
| Immunologic Memory | 3 | 2020 | 15 | 0.820 |
Why?
|
| Postpartum Period | 3 | 2024 | 85 | 0.810 |
Why?
|
| Bronchiolitis, Viral | 4 | 2016 | 9 | 0.810 |
Why?
|
| Drug Resistance, Bacterial | 14 | 2024 | 135 | 0.810 |
Why?
|
| Maternal Health Services | 2 | 2020 | 52 | 0.810 |
Why?
|
| Epidemiological Monitoring | 5 | 2019 | 45 | 0.800 |
Why?
|
| Acute Disease | 18 | 2021 | 105 | 0.800 |
Why?
|
| Anti-Infective Agents | 4 | 2023 | 57 | 0.790 |
Why?
|
| Qualitative Research | 2 | 2024 | 321 | 0.790 |
Why?
|
| Immunoglobulin A | 6 | 2023 | 39 | 0.790 |
Why?
|
| Hypertension | 3 | 2022 | 419 | 0.780 |
Why?
|
| Chorioamnionitis | 1 | 2022 | 10 | 0.780 |
Why?
|
| Meningitis, Pneumococcal | 3 | 2021 | 20 | 0.780 |
Why?
|
| Pregnant Women | 9 | 2023 | 89 | 0.770 |
Why?
|
| Isoniazid | 7 | 2023 | 110 | 0.750 |
Why?
|
| Polymerase Chain Reaction | 14 | 2018 | 260 | 0.750 |
Why?
|
| Anti-HIV Agents | 12 | 2018 | 1324 | 0.750 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2022 | 4 | 0.750 |
Why?
|
| Palivizumab | 7 | 2024 | 10 | 0.740 |
Why?
|
| Travel | 1 | 2021 | 21 | 0.730 |
Why?
|
| Malnutrition | 6 | 2024 | 56 | 0.730 |
Why?
|
| Dried Blood Spot Testing | 1 | 2021 | 24 | 0.720 |
Why?
|
| Sentinel Surveillance | 12 | 2018 | 115 | 0.720 |
Why?
|
| Maternal-Fetal Exchange | 6 | 2021 | 18 | 0.720 |
Why?
|
| Aged, 80 and over | 16 | 2024 | 468 | 0.710 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 239 | 0.710 |
Why?
|
| Vital Statistics | 1 | 2021 | 10 | 0.690 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2017 | 77 | 0.690 |
Why?
|
| Standard of Care | 2 | 2024 | 30 | 0.680 |
Why?
|
| Vaccines, Inactivated | 7 | 2018 | 23 | 0.680 |
Why?
|
| Growth and Development | 1 | 2020 | 4 | 0.680 |
Why?
|
| Maternal Exposure | 2 | 2020 | 14 | 0.670 |
Why?
|
| Unemployment | 1 | 2020 | 10 | 0.670 |
Why?
|
| Financing, Government | 1 | 2020 | 11 | 0.670 |
Why?
|
| Gender-Based Violence | 1 | 2020 | 12 | 0.660 |
Why?
|
| Hepatitis A Vaccines | 1 | 2020 | 2 | 0.660 |
Why?
|
| Wounds and Injuries | 1 | 2020 | 26 | 0.660 |
Why?
|
| Africa South of the Sahara | 11 | 2024 | 353 | 0.650 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 4 | 0.650 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 146 | 0.640 |
Why?
|
| Asia | 11 | 2024 | 72 | 0.640 |
Why?
|
| Otitis Media | 4 | 2017 | 6 | 0.640 |
Why?
|
| Infant Mortality | 7 | 2024 | 97 | 0.640 |
Why?
|
| Mass Screening | 3 | 2020 | 245 | 0.630 |
Why?
|
| Violence | 1 | 2020 | 68 | 0.630 |
Why?
|
| Genetic Variation | 8 | 2019 | 175 | 0.630 |
Why?
|
| Vitamin D Deficiency | 4 | 2022 | 27 | 0.630 |
Why?
|
| Viremia | 1 | 2020 | 66 | 0.630 |
Why?
|
| Communicable Diseases | 6 | 2023 | 62 | 0.630 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2019 | 2 | 0.620 |
Why?
|
| Environmental Exposure | 2 | 2017 | 45 | 0.620 |
Why?
|
| Comorbidity | 9 | 2024 | 188 | 0.620 |
Why?
|
| Poliovirus | 1 | 2019 | 2 | 0.620 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2017 | 472 | 0.620 |
Why?
|
| Infant, Premature, Diseases | 3 | 2022 | 19 | 0.620 |
Why?
|
| Biomarkers | 9 | 2022 | 327 | 0.620 |
Why?
|
| RNA, Viral | 8 | 2020 | 303 | 0.610 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 6 | 2020 | 31 | 0.610 |
Why?
|
| Noncommunicable Diseases | 1 | 2020 | 77 | 0.600 |
Why?
|
| Antigens, Bacterial | 6 | 2019 | 32 | 0.600 |
Why?
|
| Respiratory Sounds | 4 | 2023 | 10 | 0.600 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2017 | 59 | 0.600 |
Why?
|
| Logistic Models | 8 | 2021 | 254 | 0.600 |
Why?
|
| Registries | 2 | 2019 | 91 | 0.600 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2024 | 37 | 0.590 |
Why?
|
| Hepatitis B Antibodies | 2 | 2019 | 10 | 0.580 |
Why?
|
| Pyrazinamide | 1 | 2018 | 14 | 0.570 |
Why?
|
| Survival Analysis | 11 | 2021 | 149 | 0.570 |
Why?
|
| Sequence Analysis, DNA | 10 | 2020 | 181 | 0.570 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2018 | 20 | 0.560 |
Why?
|
| Gastric Juice | 2 | 2017 | 6 | 0.560 |
Why?
|
| Polyomavirus | 2 | 2014 | 3 | 0.560 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2017 | 5 | 0.560 |
Why?
|
| Influenza A virus | 5 | 2017 | 28 | 0.560 |
Why?
|
| Maternal-Child Health Services | 1 | 2018 | 11 | 0.560 |
Why?
|
| Containment of Biohazards | 1 | 2017 | 1 | 0.540 |
Why?
|
| Developed Countries | 5 | 2017 | 24 | 0.540 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2017 | 9 | 0.540 |
Why?
|
| Delivery, Obstetric | 1 | 2018 | 79 | 0.540 |
Why?
|
| Malaria | 4 | 2024 | 213 | 0.530 |
Why?
|
| CD4 Lymphocyte Count | 11 | 2016 | 656 | 0.530 |
Why?
|
| Betacoronavirus | 4 | 2020 | 52 | 0.530 |
Why?
|
| Laboratories | 1 | 2017 | 47 | 0.520 |
Why?
|
| Nose | 1 | 2016 | 2 | 0.520 |
Why?
|
| Gestational Age | 7 | 2022 | 80 | 0.520 |
Why?
|
| Intussusception | 3 | 2021 | 6 | 0.520 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2016 | 10 | 0.520 |
Why?
|
| Immunity, Cellular | 2 | 2016 | 25 | 0.510 |
Why?
|
| Animals | 10 | 2022 | 1081 | 0.510 |
Why?
|
| Hospital Mortality | 9 | 2023 | 95 | 0.500 |
Why?
|
| Tetanus Toxoid | 2 | 2013 | 14 | 0.500 |
Why?
|
| Pneumocystis carinii | 3 | 2017 | 9 | 0.500 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2015 | 13 | 0.500 |
Why?
|
| Advisory Committees | 2 | 2020 | 14 | 0.500 |
Why?
|
| Placebos | 9 | 2017 | 44 | 0.500 |
Why?
|
| Bacterial Adhesion | 1 | 2016 | 6 | 0.500 |
Why?
|
| Parainfluenza Virus 3, Human | 3 | 2005 | 5 | 0.490 |
Why?
|
| Molecular Epidemiology | 8 | 2019 | 47 | 0.490 |
Why?
|
| Antigens, Surface | 1 | 2015 | 11 | 0.480 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2013 | 20 | 0.470 |
Why?
|
| Respiratory System | 3 | 2024 | 9 | 0.470 |
Why?
|
| Disease Transmission, Infectious | 1 | 2015 | 39 | 0.470 |
Why?
|
| Surveys and Questionnaires | 6 | 2021 | 563 | 0.470 |
Why?
|
| Antibiotic Prophylaxis | 5 | 2017 | 21 | 0.470 |
Why?
|
| Spatio-Temporal Analysis | 2 | 2016 | 14 | 0.460 |
Why?
|
| Placenta | 5 | 2023 | 44 | 0.460 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 11 | 0.460 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 23 | 0.460 |
Why?
|
| Breast Feeding | 3 | 2022 | 120 | 0.460 |
Why?
|
| Bronchopneumonia | 1 | 2015 | 11 | 0.460 |
Why?
|
| Pilot Projects | 3 | 2019 | 179 | 0.450 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 2 | 0.450 |
Why?
|
| Meningitis, Meningococcal | 1 | 2014 | 17 | 0.450 |
Why?
|
| Tuberculin Test | 4 | 2022 | 49 | 0.450 |
Why?
|
| Models, Statistical | 5 | 2022 | 55 | 0.450 |
Why?
|
| United States | 7 | 2023 | 132 | 0.440 |
Why?
|
| Lymphocytes | 1 | 2014 | 20 | 0.440 |
Why?
|
| Monocytes | 1 | 2014 | 27 | 0.440 |
Why?
|
| Risk Assessment | 10 | 2023 | 225 | 0.440 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2024 | 262 | 0.440 |
Why?
|
| Whole Genome Sequencing | 3 | 2024 | 44 | 0.430 |
Why?
|
| Epidemiologic Research Design | 5 | 2017 | 6 | 0.430 |
Why?
|
| Orthomyxoviridae | 5 | 2018 | 33 | 0.430 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2005 | 19 | 0.420 |
Why?
|
| Public Health Surveillance | 6 | 2022 | 52 | 0.420 |
Why?
|
| Immunoassay | 4 | 2024 | 28 | 0.420 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 65 | 0.420 |
Why?
|
| Acinetobacter baumannii | 2 | 2023 | 11 | 0.420 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2013 | 5 | 0.420 |
Why?
|
| Developmental Disabilities | 3 | 2022 | 22 | 0.410 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 7 | 0.410 |
Why?
|
| Multivariate Analysis | 10 | 2020 | 171 | 0.410 |
Why?
|
| Mutation | 4 | 2023 | 306 | 0.400 |
Why?
|
| Hepatitis B | 2 | 2013 | 125 | 0.400 |
Why?
|
| Rural Population | 5 | 2021 | 654 | 0.400 |
Why?
|
| Risk | 4 | 2017 | 87 | 0.400 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 217 | 0.390 |
Why?
|
| Nutritional Status | 3 | 2024 | 76 | 0.390 |
Why?
|
| Mali | 10 | 2024 | 20 | 0.390 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 196 | 0.380 |
Why?
|
| Primary Prevention | 2 | 2016 | 27 | 0.380 |
Why?
|
| Perches | 2 | 2022 | 3 | 0.380 |
Why?
|
| Arthritis, Infectious | 1 | 2012 | 7 | 0.370 |
Why?
|
| Osteomyelitis | 1 | 2012 | 9 | 0.370 |
Why?
|
| Virulence Factors | 2 | 2024 | 18 | 0.370 |
Why?
|
| Meningococcal Vaccines | 3 | 2020 | 12 | 0.370 |
Why?
|
| Adenoviridae | 3 | 2021 | 39 | 0.370 |
Why?
|
| Administration, Oral | 4 | 2015 | 127 | 0.370 |
Why?
|
| Molecular Diagnostic Techniques | 6 | 2017 | 132 | 0.360 |
Why?
|
| Meningitis | 4 | 2024 | 26 | 0.360 |
Why?
|
| Injections, Intramuscular | 5 | 2023 | 31 | 0.350 |
Why?
|
| Brain Diseases | 3 | 2022 | 24 | 0.350 |
Why?
|
| Immunocompromised Host | 3 | 2020 | 34 | 0.350 |
Why?
|
| Calcitonin | 4 | 2014 | 10 | 0.340 |
Why?
|
| Protein Precursors | 4 | 2014 | 22 | 0.340 |
Why?
|
| Genome, Bacterial | 5 | 2024 | 32 | 0.340 |
Why?
|
| Lung Diseases | 4 | 2024 | 29 | 0.330 |
Why?
|
| Pregnancy Complications | 2 | 2022 | 55 | 0.330 |
Why?
|
| Bacterial Load | 5 | 2017 | 32 | 0.330 |
Why?
|
| Zambia | 5 | 2021 | 115 | 0.330 |
Why?
|
| Diarrhea, Infantile | 1 | 2010 | 2 | 0.330 |
Why?
|
| Disease Outbreaks | 3 | 2009 | 111 | 0.320 |
Why?
|
| Mozambique | 5 | 2024 | 55 | 0.320 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2022 | 198 | 0.320 |
Why?
|
| Decision Making | 1 | 2010 | 53 | 0.320 |
Why?
|
| International Cooperation | 3 | 2017 | 50 | 0.310 |
Why?
|
| Bangladesh | 8 | 2024 | 17 | 0.310 |
Why?
|
| Vaccine Potency | 2 | 2021 | 16 | 0.310 |
Why?
|
| Public Health | 5 | 2020 | 124 | 0.300 |
Why?
|
| BCG Vaccine | 5 | 2022 | 20 | 0.300 |
Why?
|
| Phagocytosis | 3 | 2015 | 15 | 0.300 |
Why?
|
| Gambia | 5 | 2021 | 13 | 0.300 |
Why?
|
| Lung | 7 | 2024 | 70 | 0.300 |
Why?
|
| Immunization, Passive | 3 | 2023 | 17 | 0.290 |
Why?
|
| Age Distribution | 6 | 2021 | 107 | 0.290 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2020 | 11 | 0.290 |
Why?
|
| Epidemiologic Studies | 2 | 2019 | 13 | 0.290 |
Why?
|
| Cost-Benefit Analysis | 6 | 2020 | 253 | 0.290 |
Why?
|
| Public Health Administration | 2 | 2020 | 14 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2022 | 106 | 0.290 |
Why?
|
| Data Collection | 3 | 2017 | 86 | 0.280 |
Why?
|
| Evolution, Molecular | 4 | 2020 | 60 | 0.280 |
Why?
|
| Genomics | 4 | 2023 | 109 | 0.280 |
Why?
|
| Age of Onset | 4 | 2019 | 32 | 0.280 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2020 | 30 | 0.280 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 4 | 2022 | 13 | 0.270 |
Why?
|
| Feces | 4 | 2017 | 30 | 0.270 |
Why?
|
| Sierra Leone | 4 | 2024 | 11 | 0.270 |
Why?
|
| Penicillins | 5 | 2024 | 25 | 0.270 |
Why?
|
| Enterovirus Infections | 3 | 2017 | 10 | 0.260 |
Why?
|
| Enterovirus D, Human | 3 | 2017 | 10 | 0.260 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 46 | 0.260 |
Why?
|
| Respirovirus Infections | 2 | 2005 | 3 | 0.260 |
Why?
|
| Caliciviridae Infections | 2 | 2017 | 11 | 0.260 |
Why?
|
| Odds Ratio | 7 | 2021 | 133 | 0.260 |
Why?
|
| Treatment Failure | 3 | 2021 | 175 | 0.250 |
Why?
|
| Research Design | 3 | 2017 | 124 | 0.250 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2023 | 48 | 0.250 |
Why?
|
| Sex Factors | 5 | 2020 | 227 | 0.250 |
Why?
|
| Prognosis | 5 | 2019 | 199 | 0.250 |
Why?
|
| History, 21st Century | 5 | 2019 | 42 | 0.250 |
Why?
|
| Vitamin D | 4 | 2022 | 41 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 127 | 0.250 |
Why?
|
| Oropharynx | 6 | 2017 | 17 | 0.250 |
Why?
|
| Adjuvants, Immunologic | 2 | 2024 | 23 | 0.250 |
Why?
|
| Caregivers | 2 | 2024 | 76 | 0.240 |
Why?
|
| Internationality | 7 | 2019 | 36 | 0.240 |
Why?
|
| Disease Progression | 3 | 2023 | 154 | 0.240 |
Why?
|
| Length of Stay | 2 | 2022 | 43 | 0.240 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2012 | 187 | 0.240 |
Why?
|
| Poisson Distribution | 3 | 2020 | 18 | 0.240 |
Why?
|
| Thorax | 2 | 2020 | 3 | 0.240 |
Why?
|
| Family Characteristics | 4 | 2016 | 135 | 0.230 |
Why?
|
| Half-Life | 1 | 2025 | 22 | 0.230 |
Why?
|
| Health Resources | 4 | 2018 | 66 | 0.230 |
Why?
|
| Birth Weight | 2 | 2022 | 80 | 0.230 |
Why?
|
| United Kingdom | 2 | 2021 | 33 | 0.230 |
Why?
|
| Kenya | 6 | 2024 | 183 | 0.230 |
Why?
|
| Latex Fixation Tests | 2 | 2015 | 8 | 0.230 |
Why?
|
| Regression Analysis | 4 | 2017 | 133 | 0.230 |
Why?
|
| Amoxicillin | 1 | 2004 | 9 | 0.220 |
Why?
|
| Hypoxia | 2 | 2024 | 12 | 0.220 |
Why?
|
| Geographic Mapping | 1 | 2024 | 3 | 0.220 |
Why?
|
| Genetic Fitness | 1 | 2024 | 7 | 0.220 |
Why?
|
| Africa, Southern | 2 | 2023 | 91 | 0.220 |
Why?
|
| Network Meta-Analysis | 1 | 2024 | 8 | 0.220 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 18 | 0.220 |
Why?
|
| Disease Eradication | 1 | 2024 | 11 | 0.220 |
Why?
|
| Respiratory Tract Diseases | 2 | 2021 | 21 | 0.220 |
Why?
|
| Lipoproteins | 2 | 2017 | 13 | 0.220 |
Why?
|
| Fimbriae, Bacterial | 2 | 2015 | 10 | 0.220 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2024 | 3 | 0.220 |
Why?
|
| Auscultation | 2 | 2022 | 6 | 0.220 |
Why?
|
| Hemagglutinins | 2 | 2022 | 5 | 0.220 |
Why?
|
| HLA-DRB1 Chains | 1 | 2024 | 17 | 0.220 |
Why?
|
| Tuberculosis Vaccines | 2 | 2022 | 8 | 0.220 |
Why?
|
| Observational Studies as Topic | 3 | 2019 | 21 | 0.210 |
Why?
|
| European Union | 1 | 2023 | 3 | 0.210 |
Why?
|
| Physical Examination | 2 | 2015 | 10 | 0.210 |
Why?
|
| Oxidoreductases | 1 | 2023 | 7 | 0.210 |
Why?
|
| Vitamin A Deficiency | 1 | 2023 | 5 | 0.210 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 47 | 0.210 |
Why?
|
| Adhesins, Bacterial | 2 | 2015 | 12 | 0.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2024 | 151 | 0.210 |
Why?
|
| Interviews as Topic | 1 | 2024 | 203 | 0.210 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2015 | 33 | 0.210 |
Why?
|
| Parturition | 1 | 2023 | 31 | 0.210 |
Why?
|
| Health Care Costs | 2 | 2016 | 115 | 0.200 |
Why?
|
| Neural Tube Defects | 1 | 2023 | 6 | 0.200 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2023 | 22 | 0.200 |
Why?
|
| Argentina | 3 | 2020 | 11 | 0.200 |
Why?
|
| Symptom Assessment | 3 | 2019 | 16 | 0.200 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2023 | 36 | 0.200 |
Why?
|
| Malawi | 4 | 2024 | 87 | 0.200 |
Why?
|
| Ribs | 1 | 2023 | 4 | 0.200 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2023 | 7 | 0.200 |
Why?
|
| Heart Defects, Congenital | 1 | 2023 | 12 | 0.200 |
Why?
|
| Vaccines, Subunit | 2 | 2020 | 8 | 0.200 |
Why?
|
| Asia, Southeastern | 2 | 2023 | 7 | 0.200 |
Why?
|
| Interferon-gamma | 3 | 2022 | 39 | 0.200 |
Why?
|
| Europe | 4 | 2022 | 56 | 0.200 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2017 | 15 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 60 | 0.190 |
Why?
|
| Parainfluenza Virus 1, Human | 1 | 2002 | 2 | 0.190 |
Why?
|
| Parainfluenza Virus 2, Human | 1 | 2002 | 2 | 0.190 |
Why?
|
| Lymphadenopathy | 1 | 2022 | 4 | 0.190 |
Why?
|
| Saliva | 2 | 2019 | 22 | 0.190 |
Why?
|
| Maternal Health | 2 | 2019 | 20 | 0.190 |
Why?
|
| Outpatients | 3 | 2017 | 38 | 0.190 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 21 | 0.190 |
Why?
|
| Metagenomics | 1 | 2022 | 13 | 0.190 |
Why?
|
| Pulmonary Alveoli | 1 | 2002 | 1 | 0.190 |
Why?
|
| Stethoscopes | 1 | 2022 | 2 | 0.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 34 | 0.190 |
Why?
|
| Respiratory Function Tests | 2 | 2020 | 10 | 0.190 |
Why?
|
| Radiography | 4 | 2020 | 80 | 0.190 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2022 | 8 | 0.190 |
Why?
|
| Ethiopia | 4 | 2024 | 18 | 0.190 |
Why?
|
| Chlorides | 1 | 2022 | 2 | 0.190 |
Why?
|
| Zinc Compounds | 1 | 2022 | 2 | 0.190 |
Why?
|
| Aircraft | 1 | 2021 | 3 | 0.190 |
Why?
|
| Opsonin Proteins | 2 | 2012 | 4 | 0.180 |
Why?
|
| Birth Rate | 1 | 2021 | 5 | 0.180 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2021 | 2 | 0.180 |
Why?
|
| Infant Health | 1 | 2021 | 16 | 0.180 |
Why?
|
| Disease Management | 3 | 2019 | 74 | 0.180 |
Why?
|
| Seizures | 1 | 2021 | 20 | 0.180 |
Why?
|
| Seizures, Febrile | 1 | 2021 | 3 | 0.180 |
Why?
|
| Paramyxovirinae | 1 | 2021 | 2 | 0.180 |
Why?
|
| Intestinal Perforation | 1 | 2021 | 5 | 0.180 |
Why?
|
| Cross Reactions | 1 | 2021 | 44 | 0.180 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 39 | 0.180 |
Why?
|
| Safety | 1 | 2021 | 34 | 0.180 |
Why?
|
| Neisseria meningitidis | 2 | 2018 | 36 | 0.180 |
Why?
|
| Asymptomatic Infections | 2 | 2021 | 34 | 0.180 |
Why?
|
| Patient Discharge | 1 | 2021 | 27 | 0.170 |
Why?
|
| Physical and Rehabilitation Medicine | 1 | 2020 | 1 | 0.170 |
Why?
|
| Health Planning | 1 | 2020 | 13 | 0.170 |
Why?
|
| Dominican Republic | 2 | 2018 | 2 | 0.170 |
Why?
|
| Panama | 2 | 2018 | 2 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 176 | 0.170 |
Why?
|
| Jordan | 1 | 2020 | 1 | 0.170 |
Why?
|
| Health Equity | 1 | 2020 | 12 | 0.170 |
Why?
|
| Cytokines | 1 | 2021 | 107 | 0.170 |
Why?
|
| Enterovirus | 2 | 2017 | 9 | 0.170 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 30 | 0.170 |
Why?
|
| Single-Blind Method | 2 | 2020 | 17 | 0.170 |
Why?
|
| Health Behavior | 1 | 2021 | 79 | 0.170 |
Why?
|
| Biomedical Research | 2 | 2018 | 49 | 0.170 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.170 |
Why?
|
| Urban Population | 4 | 2021 | 257 | 0.170 |
Why?
|
| Microscopy | 2 | 2017 | 21 | 0.170 |
Why?
|
| Calcitonin Gene-Related Peptide | 4 | 2014 | 8 | 0.170 |
Why?
|
| DNA Transposable Elements | 1 | 2020 | 4 | 0.170 |
Why?
|
| Isoantibodies | 1 | 2020 | 15 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 62 | 0.170 |
Why?
|
| Herpesvirus 3, Human | 1 | 2020 | 3 | 0.170 |
Why?
|
| Ultrasonography | 1 | 2020 | 77 | 0.170 |
Why?
|
| Obesity | 2 | 2020 | 367 | 0.160 |
Why?
|
| Child, Hospitalized | 5 | 2019 | 26 | 0.160 |
Why?
|
| Meningococcal Infections | 1 | 2020 | 24 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2020 | 49 | 0.160 |
Why?
|
| Rubella | 1 | 2019 | 5 | 0.160 |
Why?
|
| Rubella virus | 1 | 2019 | 8 | 0.160 |
Why?
|
| HLA Antigens | 1 | 2020 | 50 | 0.160 |
Why?
|
| Maternal Mortality | 1 | 2020 | 58 | 0.160 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 21 | 0.160 |
Why?
|
| Diagnosis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 13 | 0.160 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 1999 | 3 | 0.160 |
Why?
|
| Cation Transport Proteins | 1 | 2019 | 3 | 0.160 |
Why?
|
| Health Status | 2 | 2018 | 111 | 0.160 |
Why?
|
| Primary Health Care | 2 | 2020 | 240 | 0.160 |
Why?
|
| 5' Untranslated Regions | 1 | 2019 | 7 | 0.160 |
Why?
|
| Software | 1 | 2019 | 37 | 0.160 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 5 | 0.160 |
Why?
|
| Taxes | 1 | 2020 | 73 | 0.160 |
Why?
|
| Hypergammaglobulinemia | 1 | 2019 | 3 | 0.160 |
Why?
|
| Genes, Bacterial | 5 | 2019 | 23 | 0.160 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 38 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2019 | 65 | 0.160 |
Why?
|
| Ureaplasma | 1 | 2019 | 4 | 0.150 |
Why?
|
| Vietnam | 1 | 2019 | 13 | 0.150 |
Why?
|
| Placenta Diseases | 1 | 2019 | 5 | 0.150 |
Why?
|
| Anemia | 1 | 2019 | 41 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 7 | 0.150 |
Why?
|
| Blood Culture | 1 | 2019 | 11 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 237 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 43 | 0.150 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2019 | 1 | 0.150 |
Why?
|
| Child Development | 1 | 2020 | 93 | 0.150 |
Why?
|
| Hemagglutination | 1 | 2018 | 3 | 0.150 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 56 | 0.150 |
Why?
|
| Mamastrovirus | 1 | 2018 | 3 | 0.150 |
Why?
|
| Astroviridae Infections | 1 | 2018 | 3 | 0.150 |
Why?
|
| Antibodies | 1 | 2018 | 25 | 0.150 |
Why?
|
| Analysis of Variance | 2 | 2016 | 64 | 0.150 |
Why?
|
| Serum | 2 | 2015 | 9 | 0.150 |
Why?
|
| Vaccines, Acellular | 1 | 2018 | 1 | 0.150 |
Why?
|
| Statistics as Topic | 2 | 2015 | 31 | 0.150 |
Why?
|
| ROC Curve | 5 | 2017 | 51 | 0.150 |
Why?
|
| Physicians | 1 | 2018 | 31 | 0.150 |
Why?
|
| Bronchiolitis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Molecular Sequence Data | 7 | 2014 | 263 | 0.150 |
Why?
|
| Nurses | 1 | 2018 | 32 | 0.140 |
Why?
|
| Streptococcus pyogenes | 1 | 2018 | 5 | 0.140 |
Why?
|
| Pharynx | 1 | 2018 | 4 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 139 | 0.140 |
Why?
|
| Chi-Square Distribution | 2 | 2020 | 45 | 0.140 |
Why?
|
| Transportation | 1 | 2018 | 7 | 0.140 |
Why?
|
| Maternal Age | 1 | 2018 | 22 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2024 | 48 | 0.140 |
Why?
|
| Kinetics | 1 | 2017 | 65 | 0.140 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 163 | 0.140 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 6 | 0.130 |
Why?
|
| Norovirus | 1 | 2017 | 5 | 0.130 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2017 | 21 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2017 | 64 | 0.130 |
Why?
|
| Immunoglobulin D | 1 | 2017 | 4 | 0.130 |
Why?
|
| Drug Administration Schedule | 5 | 2022 | 156 | 0.130 |
Why?
|
| Carrier Proteins | 1 | 2017 | 23 | 0.130 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 63 | 0.130 |
Why?
|
| Virus Shedding | 3 | 2013 | 24 | 0.130 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 411 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 40 | 0.130 |
Why?
|
| Live Birth | 1 | 2016 | 5 | 0.130 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2016 | 10 | 0.120 |
Why?
|
| Sapovirus | 1 | 2016 | 6 | 0.120 |
Why?
|
| Plakophilins | 1 | 2016 | 1 | 0.120 |
Why?
|
| Drug Resistance, Microbial | 3 | 2000 | 26 | 0.120 |
Why?
|
| Linear Models | 3 | 2020 | 83 | 0.120 |
Why?
|
| N-Acetylmuramoyl-L-alanine Amidase | 2 | 2017 | 5 | 0.120 |
Why?
|
| Reference Standards | 4 | 2019 | 29 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 43 | 0.120 |
Why?
|
| Exudates and Transudates | 1 | 2015 | 2 | 0.120 |
Why?
|
| Microbial Interactions | 1 | 2015 | 2 | 0.120 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2015 | 10 | 0.120 |
Why?
|
| Pneumovirus Infections | 1 | 2015 | 7 | 0.120 |
Why?
|
| Tertiary Care Centers | 3 | 2020 | 80 | 0.120 |
Why?
|
| Mice | 2 | 2012 | 135 | 0.120 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 7 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 279 | 0.110 |
Why?
|
| Vaccines, Synthetic | 2 | 2024 | 12 | 0.110 |
Why?
|
| Suburban Population | 1 | 2014 | 9 | 0.110 |
Why?
|
| Immunologic Techniques | 1 | 2014 | 4 | 0.110 |
Why?
|
| HIV Protease Inhibitors | 1 | 2015 | 92 | 0.110 |
Why?
|
| Organizational Objectives | 1 | 2014 | 6 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2011 | 56 | 0.110 |
Why?
|
| Paramyxoviridae | 1 | 2014 | 1 | 0.110 |
Why?
|
| Bocavirus | 1 | 2014 | 1 | 0.110 |
Why?
|
| Immunogenetic Phenomena | 1 | 2014 | 7 | 0.110 |
Why?
|
| Nepal | 3 | 2020 | 6 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2013 | 31 | 0.110 |
Why?
|
| Models, Immunological | 1 | 2013 | 2 | 0.110 |
Why?
|
| Nasopharyngeal Diseases | 1 | 2013 | 1 | 0.100 |
Why?
|
| Drug Discovery | 2 | 2023 | 23 | 0.100 |
Why?
|
| Child Day Care Centers | 1 | 2013 | 4 | 0.100 |
Why?
|
| Culture Media | 1 | 2013 | 15 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 4 | 2017 | 22 | 0.100 |
Why?
|
| Thailand | 3 | 2017 | 26 | 0.100 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 76 | 0.100 |
Why?
|
| Vitamins | 2 | 2023 | 23 | 0.100 |
Why?
|
| DNA, Viral | 2 | 2011 | 165 | 0.100 |
Why?
|
| Bacterial Typing Techniques | 2 | 2009 | 11 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 12 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2024 | 107 | 0.100 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2012 | 6 | 0.100 |
Why?
|
| Administrative Personnel | 1 | 2012 | 17 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 45 | 0.100 |
Why?
|
| China | 2 | 2024 | 21 | 0.090 |
Why?
|
| Child Welfare | 1 | 2012 | 16 | 0.090 |
Why?
|
| Latin America | 1 | 2012 | 10 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2003 | 24 | 0.090 |
Why?
|
| Child Nutrition Disorders | 2 | 2024 | 13 | 0.090 |
Why?
|
| Infant Death | 2 | 2022 | 2 | 0.090 |
Why?
|
| Colony Count, Microbial | 1 | 2011 | 14 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 39 | 0.090 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 2 | 0.090 |
Why?
|
| Frameshift Mutation | 1 | 2011 | 3 | 0.090 |
Why?
|
| Bacteriocins | 1 | 2011 | 5 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 61 | 0.090 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 21 | 0.090 |
Why?
|
| Preventive Health Services | 1 | 2011 | 17 | 0.090 |
Why?
|
| Infection Control | 1 | 2011 | 31 | 0.090 |
Why?
|
| Neutralization Tests | 2 | 2022 | 108 | 0.090 |
Why?
|
| Fetal Blood | 2 | 2022 | 27 | 0.090 |
Why?
|
| Research | 2 | 2022 | 65 | 0.090 |
Why?
|
| Virus Cultivation | 1 | 2011 | 9 | 0.090 |
Why?
|
| Mycobacterium | 1 | 2011 | 16 | 0.090 |
Why?
|
| Iron | 2 | 2022 | 32 | 0.090 |
Why?
|
| Oxygen | 2 | 2023 | 25 | 0.090 |
Why?
|
| Virulence | 2 | 2011 | 25 | 0.080 |
Why?
|
| Penicillin Resistance | 2 | 2024 | 17 | 0.080 |
Why?
|
| Multilocus Sequence Typing | 2 | 2020 | 19 | 0.080 |
Why?
|
| Fever | 2 | 2019 | 26 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 2 | 0.080 |
Why?
|
| Vancomycin | 2 | 2020 | 6 | 0.080 |
Why?
|
| Depression, Postpartum | 1 | 2010 | 22 | 0.080 |
Why?
|
| Pediatrics | 1 | 2010 | 17 | 0.080 |
Why?
|
| Skin Tests | 2 | 2000 | 14 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 106 | 0.080 |
Why?
|
| Mother-Child Relations | 1 | 2010 | 20 | 0.080 |
Why?
|
| Databases, Genetic | 2 | 2020 | 22 | 0.080 |
Why?
|
| Chlorhexidine | 1 | 2009 | 10 | 0.080 |
Why?
|
| Algorithms | 2 | 2022 | 106 | 0.080 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2009 | 16 | 0.080 |
Why?
|
| Skin | 1 | 2009 | 38 | 0.080 |
Why?
|
| Australia | 2 | 2021 | 48 | 0.080 |
Why?
|
| Labor, Obstetric | 1 | 2009 | 44 | 0.080 |
Why?
|
| Escherichia coli | 2 | 2023 | 30 | 0.080 |
Why?
|
| Vitamin D-Binding Protein | 2 | 2021 | 4 | 0.080 |
Why?
|
| Apnea | 1 | 2008 | 2 | 0.070 |
Why?
|
| Probability | 2 | 2005 | 27 | 0.070 |
Why?
|
| Financing, Organized | 1 | 2008 | 3 | 0.070 |
Why?
|
| Family | 2 | 2022 | 35 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2007 | 7 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2017 | 22 | 0.070 |
Why?
|
| Geography | 2 | 2021 | 60 | 0.070 |
Why?
|
| Health Personnel | 2 | 2021 | 231 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2007 | 30 | 0.070 |
Why?
|
| Survival Rate | 2 | 2013 | 96 | 0.070 |
Why?
|
| Antigens, Viral | 2 | 2020 | 21 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 198 | 0.060 |
Why?
|
| Inpatients | 2 | 2017 | 30 | 0.060 |
Why?
|
| Brazil | 2 | 2020 | 47 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2016 | 82 | 0.060 |
Why?
|
| Interferons | 1 | 2006 | 9 | 0.060 |
Why?
|
| Blood | 1 | 2006 | 51 | 0.060 |
Why?
|
| Immunity | 1 | 2005 | 10 | 0.060 |
Why?
|
| Base Sequence | 3 | 2012 | 149 | 0.060 |
Why?
|
| Observer Variation | 1 | 2005 | 15 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2019 | 101 | 0.060 |
Why?
|
| Viral Proteins | 1 | 2005 | 30 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 64 | 0.060 |
Why?
|
| African Americans | 1 | 2005 | 47 | 0.060 |
Why?
|
| Parainfluenza Vaccines | 1 | 2004 | 1 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 40 | 0.060 |
Why?
|
| Meningitis, Haemophilus | 1 | 2004 | 1 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 11 | 0.060 |
Why?
|
| Cluster Analysis | 3 | 2011 | 65 | 0.060 |
Why?
|
| Mannose-Binding Lectin | 1 | 2004 | 1 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2024 | 56 | 0.060 |
Why?
|
| Locomotion | 1 | 2024 | 3 | 0.060 |
Why?
|
| Quantitative Trait Loci | 1 | 2024 | 7 | 0.050 |
Why?
|
| Ghrelin | 1 | 2024 | 2 | 0.050 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2024 | 3 | 0.050 |
Why?
|
| Morbidity | 2 | 2015 | 37 | 0.050 |
Why?
|
| CD59 Antigens | 1 | 2024 | 1 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2004 | 89 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 34 | 0.050 |
Why?
|
| Leptin | 1 | 2024 | 26 | 0.050 |
Why?
|
| Zimbabwe | 1 | 2024 | 120 | 0.050 |
Why?
|
| Vitamin A | 1 | 2023 | 10 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2023 | 38 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 22 | 0.050 |
Why?
|
| Uganda | 1 | 2024 | 197 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2023 | 39 | 0.050 |
Why?
|
| Receptors, Fc | 1 | 2023 | 10 | 0.050 |
Why?
|
| Virus Replication | 1 | 2024 | 88 | 0.050 |
Why?
|
| Liver | 1 | 2023 | 74 | 0.050 |
Why?
|
| Folic Acid | 1 | 2023 | 12 | 0.050 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 48 | 0.050 |
Why?
|
| Term Birth | 1 | 2023 | 5 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2023 | 73 | 0.050 |
Why?
|
| Oximetry | 1 | 2023 | 6 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2023 | 9 | 0.050 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 17 | 0.050 |
Why?
|
| Shock, Septic | 1 | 2003 | 10 | 0.050 |
Why?
|
| Case Management | 1 | 2022 | 5 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 18 | 0.050 |
Why?
|
| Thinness | 1 | 2022 | 18 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2002 | 8 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 2011 | 139 | 0.050 |
Why?
|
| Pneumocystis | 1 | 2002 | 1 | 0.050 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 1 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 5 | 0.050 |
Why?
|
| Biopsy | 1 | 2002 | 38 | 0.050 |
Why?
|
| Lopinavir | 2 | 2015 | 137 | 0.050 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 11 | 0.050 |
Why?
|
| Heart Diseases | 1 | 2022 | 19 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 42 | 0.050 |
Why?
|
| Ritonavir | 2 | 2015 | 137 | 0.050 |
Why?
|
| Global Burden of Disease | 1 | 2021 | 5 | 0.050 |
Why?
|
| Income | 1 | 2022 | 85 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2021 | 19 | 0.050 |
Why?
|
| Enema | 1 | 2021 | 3 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2021 | 23 | 0.040 |
Why?
|
| Vero Cells | 1 | 2021 | 6 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 10 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2021 | 12 | 0.040 |
Why?
|
| Antigen-Antibody Complex | 1 | 2021 | 11 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 104 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 22 | 0.040 |
Why?
|
| Cameroon | 1 | 2021 | 9 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 188 | 0.040 |
Why?
|
| Absorption, Physiological | 1 | 2021 | 2 | 0.040 |
Why?
|
| Sickle Cell Trait | 1 | 2021 | 3 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 3 | 0.040 |
Why?
|
| Hepcidins | 1 | 2021 | 6 | 0.040 |
Why?
|
| Dyspnea | 1 | 2020 | 10 | 0.040 |
Why?
|
| Headache | 1 | 2020 | 7 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 11 | 0.040 |
Why?
|
| Fatigue | 1 | 2020 | 20 | 0.040 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 13 | 0.040 |
Why?
|
| Clindamycin | 1 | 2020 | 3 | 0.040 |
Why?
|
| Erythromycin | 1 | 2020 | 12 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 4 | 0.040 |
Why?
|
| Haplotypes | 1 | 2021 | 125 | 0.040 |
Why?
|
| Adenovirus Infections, Human | 1 | 2000 | 3 | 0.040 |
Why?
|
| Health Impact Assessment | 1 | 2020 | 1 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 17 | 0.040 |
Why?
|
| Placental Circulation | 1 | 2020 | 6 | 0.040 |
Why?
|
| Levofloxacin | 1 | 2020 | 21 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 16 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 2020 | 11 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 16 | 0.040 |
Why?
|
| Poland | 1 | 2020 | 3 | 0.040 |
Why?
|
| Utah | 1 | 2020 | 3 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2020 | 22 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2000 | 26 | 0.040 |
Why?
|
| Phylogeography | 1 | 2020 | 15 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 19 | 0.040 |
Why?
|
| Tetracycline Resistance | 1 | 2020 | 4 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 62 | 0.040 |
Why?
|
| Nasal Lavage Fluid | 1 | 2020 | 2 | 0.040 |
Why?
|
| Geography, Medical | 1 | 2019 | 3 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 34 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 97 | 0.040 |
Why?
|
| Genome | 1 | 2019 | 9 | 0.040 |
Why?
|
| Burial | 1 | 2019 | 2 | 0.040 |
Why?
|
| Molecular Typing | 1 | 2019 | 12 | 0.040 |
Why?
|
| Chloramphenicol | 1 | 1999 | 1 | 0.040 |
Why?
|
| Social Networking | 1 | 2019 | 8 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2019 | 26 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1999 | 4 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 35 | 0.040 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2019 | 10 | 0.040 |
Why?
|
| Fluoroquinolones | 1 | 1999 | 20 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2019 | 20 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 15 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2019 | 11 | 0.040 |
Why?
|
| Drug Approval | 1 | 2019 | 3 | 0.040 |
Why?
|
| Proteins | 1 | 2019 | 20 | 0.040 |
Why?
|
| Antigen-Presenting Cells | 1 | 2019 | 2 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 24 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 80 | 0.040 |
Why?
|
| Biodiversity | 1 | 2019 | 11 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 24 | 0.040 |
Why?
|
| Anniversaries and Special Events | 1 | 2018 | 2 | 0.040 |
Why?
|
| Genome, Human | 1 | 2019 | 25 | 0.040 |
Why?
|
| Obstetrics | 1 | 2018 | 10 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2018 | 26 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2019 | 87 | 0.040 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2018 | 19 | 0.040 |
Why?
|
| Technology Transfer | 1 | 2018 | 1 | 0.040 |
Why?
|
| Legislation, Drug | 1 | 2018 | 2 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 4 | 0.040 |
Why?
|
| Rifampin | 1 | 1999 | 197 | 0.040 |
Why?
|
| Self Report | 1 | 2018 | 114 | 0.040 |
Why?
|
| Capsid Proteins | 1 | 2017 | 8 | 0.030 |
Why?
|
| Diagnostic Techniques, Respiratory System | 1 | 2017 | 1 | 0.030 |
Why?
|
| Moraxellaceae Infections | 1 | 2017 | 1 | 0.030 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2017 | 2 | 0.030 |
Why?
|
| Selection Bias | 1 | 2017 | 4 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2017 | 21 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2017 | 11 | 0.030 |
Why?
|
| Focus Groups | 1 | 2018 | 196 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 25 | 0.030 |
Why?
|
| Control Groups | 1 | 2017 | 3 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2017 | 9 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 27 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2017 | 14 | 0.030 |
Why?
|
| Administration, Intranasal | 2 | 2009 | 8 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 1 | 2017 | 6 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2017 | 38 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 53 | 0.030 |
Why?
|
| Observation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Checklist | 1 | 2016 | 5 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 52 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2016 | 22 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2016 | 20 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2016 | 15 | 0.030 |
Why?
|
| Anoctamins | 1 | 2016 | 1 | 0.030 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 2016 | 1 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2016 | 4 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 11 | 0.030 |
Why?
|
| Benchmarking | 1 | 2016 | 10 | 0.030 |
Why?
|
| Parents | 1 | 2016 | 32 | 0.030 |
Why?
|
| Gene Expression | 1 | 2016 | 43 | 0.030 |
Why?
|
| Hong Kong | 1 | 2015 | 2 | 0.030 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2015 | 8 | 0.030 |
Why?
|
| Amniotic Fluid | 1 | 2015 | 13 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 105 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2015 | 22 | 0.030 |
Why?
|
| Models, Biological | 1 | 2015 | 77 | 0.030 |
Why?
|
| Epidemiology | 1 | 2015 | 4 | 0.030 |
Why?
|
| England | 1 | 2015 | 15 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 17 | 0.030 |
Why?
|
| Endemic Diseases | 1 | 2015 | 15 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2017 | 278 | 0.030 |
Why?
|
| Adrenomedullin | 1 | 2014 | 1 | 0.030 |
Why?
|
| Capacity Building | 1 | 2015 | 32 | 0.030 |
Why?
|
| Models, Economic | 1 | 2014 | 15 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 34 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 23 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 2012 | 4 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 20 | 0.020 |
Why?
|
| North America | 1 | 2012 | 11 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 55 | 0.020 |
Why?
|
| Program Development | 1 | 2012 | 32 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 99 | 0.020 |
Why?
|
| Disease Notification | 1 | 2012 | 14 | 0.020 |
Why?
|
| Lymphadenitis | 1 | 2011 | 2 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 125 | 0.020 |
Why?
|
| Pheromones | 1 | 2011 | 5 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 11 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2012 | 66 | 0.020 |
Why?
|
| Sweden | 1 | 2011 | 5 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 111 | 0.020 |
Why?
|
| National Health Programs | 1 | 2011 | 78 | 0.020 |
Why?
|
| Social Isolation | 1 | 2010 | 5 | 0.020 |
Why?
|
| Bronchodilator Agents | 1 | 2010 | 7 | 0.020 |
Why?
|
| Infant Behavior | 1 | 2010 | 5 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 21 | 0.020 |
Why?
|
| Adsorption | 1 | 2009 | 6 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2009 | 9 | 0.020 |
Why?
|
| Infant Care | 1 | 2009 | 10 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2009 | 57 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2010 | 125 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 158 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2008 | 24 | 0.020 |
Why?
|
| Zidovudine | 1 | 2008 | 59 | 0.020 |
Why?
|
| Lamivudine | 1 | 2008 | 89 | 0.020 |
Why?
|
| Rimantadine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Contraindications | 1 | 2008 | 5 | 0.020 |
Why?
|
| Amantadine | 1 | 2008 | 6 | 0.020 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2008 | 21 | 0.020 |
Why?
|
| Indians, North American | 1 | 2007 | 2 | 0.020 |
Why?
|
| California | 1 | 2007 | 9 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 54 | 0.020 |
Why?
|
| Pharyngitis | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sinusitis | 1 | 2004 | 2 | 0.010 |
Why?
|
| Tonsillitis | 1 | 2004 | 2 | 0.010 |
Why?
|
| Bronchitis, Chronic | 1 | 2004 | 2 | 0.010 |
Why?
|
| Common Cold | 1 | 2004 | 3 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 59 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 73 | 0.010 |
Why?
|
| Nevirapine | 1 | 2002 | 146 | 0.010 |
Why?
|